167 related articles for article (PubMed ID: 32077604)
1. Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues.
Buti M; Roade L; Riveiro-Barciela M; Esteban R
Liver Int; 2020 Feb; 40 Suppl 1():15-21. PubMed ID: 32077604
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
[TBL] [Abstract][Full Text] [Related]
3. Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
Buti M; Marcos-Fosch C; Esteban R
Liver Int; 2021 Jun; 41 Suppl 1():9-14. PubMed ID: 34155802
[TBL] [Abstract][Full Text] [Related]
4. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
[TBL] [Abstract][Full Text] [Related]
5. Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.
Lim YS; Seto WK; Kurosaki M; Fung S; Kao JH; Hou J; Gordon SC; Flaherty JF; Yee LJ; Zhao Y; Agarwal K; Lampertico P
Aliment Pharmacol Ther; 2022 Apr; 55(8):921-943. PubMed ID: 35178711
[TBL] [Abstract][Full Text] [Related]
6. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794
[TBL] [Abstract][Full Text] [Related]
7. Safety of current antiviral drugs for chronic hepatitis B.
Masetti C; Pugliese N; Aghemo A; Viganò M
Expert Opin Drug Saf; 2022 Jul; 21(7):939-945. PubMed ID: 35209776
[TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand.
Dilokthornsakul P; Sawangjit R; Tangkijvanich P; Chayanupatkul M; Tanwandee T; Sukeepaisarnjaroen W; Sriuttha P; Permsuwan U
Appl Health Econ Health Policy; 2022 Jul; 20(4):587-596. PubMed ID: 35141850
[TBL] [Abstract][Full Text] [Related]
9. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
Wang HM; Hung CH; Lee CM; Lu SN; Wang JH; Yen YH; Kee KM; Chang KC; Tseng PL; Hu TH; Chen CH
J Gastroenterol Hepatol; 2016 Jul; 31(7):1307-14. PubMed ID: 26758501
[TBL] [Abstract][Full Text] [Related]
10. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
11. Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
Yip TC; Lai JC; Wong GL
J Gastroenterol; 2020 Nov; 55(11):1023-1036. PubMed ID: 32974760
[TBL] [Abstract][Full Text] [Related]
12. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy.
Hall S; Howell J; Visvanathan K; Thompson A
Viruses; 2020 Aug; 12(9):. PubMed ID: 32854335
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B.
Roade L; Riveiro-Barciela M; Esteban R; Buti M
Ther Adv Infect Dis; 2021; 8():2049936120985954. PubMed ID: 33614029
[TBL] [Abstract][Full Text] [Related]
14. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Viganò M; Mangia G; Lampertico P
Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
[TBL] [Abstract][Full Text] [Related]
15. The relationship between the use of nucleos(t)ide analogs and metabolic parameters in patients with chronic hepatitis B.
Yakut A; Aladag M
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9315-9323. PubMed ID: 37843345
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.
Buti M; Riveiro-Barciela M; Esteban R
Liver Int; 2018 Feb; 38 Suppl 1():84-89. PubMed ID: 29427500
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
[TBL] [Abstract][Full Text] [Related]
18. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N
J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880
[TBL] [Abstract][Full Text] [Related]
19. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review.
de Fraga RS; Van Vaisberg V; Mendes LCA; Carrilho FJ; Ono SK
J Gastroenterol; 2020 May; 55(5):496-514. PubMed ID: 32185517
[TBL] [Abstract][Full Text] [Related]
20. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
Kayaaslan B; Akinci E; Ari A; Tufan ZK; Alpat SN; Gunal O; Tosun S; Guner R; Tabak F
Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):40-47. PubMed ID: 28757048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
